Fact CheckerSign in

NCT02310178Recruiting

Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery

Source: ClinicalTrials.gov · Last updated 22 Jun 2026

Brief summary (registry, in English)

The aim of this cohort is to evaluate the follow-up of morbidly obese patients treated by several types of bariatric procedures. In addition, this study could lead to the development of clinical trials on assessment of the bariatric surgery impact.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
750 (estimated)
First submitted
28 Oct 2014
Start date
21 May 2012
Primary completion date
Dec 2026
Lead sponsor
University Hospital, Montpellier
Diseases
Obesity
NCT number
NCT02310178

What you commit to

  • Study type: Interventional
  • Planned participants: 750
  • From 21 May 2012 to the primary completion date, Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Unable to follow the patient in the long term (foreign patients, surgical use ...)

Other

  • Inability to follow in the long run

Who the study is looking for

  • Only be considered in patients operated and followed at CHU Montpellier with bariatric surgery
  • Patients treated by bariatric surgery on CHU Montpellier
  • Agreed to participate to the study by signing an informed consent
  • Eligible to health insurance

Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHRU - Hôpital Saint Eloi
Coordinator of this site? Confirm its status
MontpellierFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.